Study of Patient-Recorded Weight and Activity to Improve Cancer Cachexia Diagnosis in Adults Undergoing Curative Surgery or Chemotherapy

What this Trial Is About

Researchers are investigating cachexia, a syndrome involving significant loss of body weight and muscle mass that affects cancer patients quality of life, survival, and treatment outcomes. The study aims to improve the accuracy of cachexia diagnosis by comparing self-reported weight changes with objective measurements taken before treatment. This pilot study involves patients aged 18 and older undergoing curative-intent chemotherapy or surgery for various cancers, including upper gastrointestinal, hepatobiliary, pancreatic, colorectal, and ovarian cancers. Participants will undergo extensive pre-treatment assessments including physical tests, body measurements, and laboratory tests. They will receive a weight scale and an accelerometer to measure daily body weight and physical activity at home. For chemotherapy patients, monitoring starts at initial clinic presentation, continues through treatment, and ends two weeks after chemotherapy. For surgical patients, monitoring pauses during hospital stay and resumes after discharge until follow-up. Imaging and body composition analyses will be performed before and after treatment. Throughout the study, researchers will record treatment-related adverse events, response to therapy, survival, and disease-free survival for up to five years. Physical activity, body composition, and other cachexia-related parameters will also be analyzed. Data will be collected via tests, scans, questionnaires, and equipment use, with adverse events classified by established criteria. This comprehensive monitoring aims to better understand cachexias impact and improve diagnosis accuracy in cancer care.

Patient Recorded Indexing Measurements